Rene M.
- Country
- Germany
- Department
- Department Urology and Pediatric Urology
Research Overview
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
- Phase 3 Randomized, Double-Blind Study of Cabozantinib, Nivolumab, and Ipilimumab in Untreated Advanced or Metastatic Renal Cell Carcinoma
Data & Insights
Has run more than one trial at 14 of 96 partner sites.
Specializations
Renal Cancer Specialization
This investigator demonstrates focused expertise in advanced renal cell carcinoma (RCC), with particular emphasis on treating both localized and metastatic disease states.
- Post-surgical Treatment Approaches
- Advanced Stage RCC Management
- Metastatic Disease Interventions
The investigator's work encompasses comprehensive care strategies for various stages of renal cancer progression.
Immunotherapy Applications
Specialized focus on immune checkpoint inhibitor therapies in renal cancer treatment, including evaluation of novel combination approaches.
- Monotherapy Protocols
- Combination Immunotherapy
- Treatment-naive Patient Care
The investigator explores innovative immunotherapeutic strategies for enhanced patient outcomes.
Risk-Stratified Treatment
Expertise in developing therapeutic approaches for intermediate and poor-risk RCC patients, with attention to personalized treatment strategies.
- Risk-based Treatment Selection
- Disease State Management
- Treatment Response Assessment
Focus includes tailored therapeutic interventions based on patient risk classification.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.